Symptomtext
administered FLUZONE QIV NP after the expiration date with no reported adverse event; Initial information received on 16-Sep-2022 regarding an unsolicited valid non-serious case received from a pediatrician. This case involves a 15-year-old male patient to whom INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QIV] np was administered after the expiration date with no reported adverse event while receiving vaccine. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 15-Sep-2022, the patient received suspect Fluzone QIV at dose 0.5ml once via intramuscular route in the left deltoid (lot: UT7407MA, expiry date: 30-Jun-2022) for prophylactic vaccination with no reported adverse event (expired product administered) at latency same day. Action taken: Not applicable. At time of reporting, the outcome was Unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.